SPRO at a glance
Spero Therapeutics Inc (SPRO, SEC CIK 1701108) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 10, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Spero Therapeutics Inc (SPRO) reported revenue of $12.6 million (up 3292.5% from FY2024) and net income of $8.6 million. Diluted EPS was $0.15.
- As of September 30, 2026, 17 institutional investment managers tracked by SignalX reported holding Spero Therapeutics Inc (SPRO) shares worth $11.3 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Rajavelu Esther on November 9, 2026 of 40,851 shares at $1.04 per share.
- In the last 90 days, SPRO insiders reported 0 open-market purchases ($0) and 1 open-market sale ($42K) on Form 4, a net sale of $42K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $12.6M
- +3292.5% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$42K
- 13F holders
- 17 funds
- $11.3M · −3 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- New lead-candidate dependence: July 8, 2026 Innovent Agreement shifted focus to SP001, now the only clinical-stage candidate
- Most material update: Utebzi FDA approval and SPR206/SPR720 termination increased reliance on SP001 development and GSK commercialization
- Regulatory risk: May 2026 House draft report could bar FDA consideration of China-generated clinical data supporting SP001’s IND
- Competitive risk: SP001 faces approved UPLIZNA and multiple IgG4-related disease candidates in development
- Liquidity risk: $105.0 million HCRx Notes limit retained GSK proceeds to 35% after repayment terms
Management Discussion & Analysis
- Quarterly revenue $0 vs $5.442M YoY, reflecting no grant or collaboration revenue
- Net loss $44.278M vs $7.382M YoY, operating loss $41.913M vs $7.916M
- Worst-performing line: grant revenue $0 vs $2.394M, collaboration revenue $0 vs $3.048M
- Cash $107.9M; operating cash use $32.098M, financing provided $99.761M from milestone and royalty financing
- SP001 Phase 2 IgG4-RD trial expected Q2 2027, subject to FDA IND clearance; funding projected into second half of 2029
AI summary of the SPRO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Third-quarter results for period ended September 30, 2026 announced by Spero Therapeutics
- Press release contains the financial results and management commentary, furnished as Exhibit 99.1
Item EX-99.1: Item EX-99.1
- SP001 Phase 2 IgG4-RD study targeted for Q2 2027, establishing the company’s next major clinical catalyst
- $107.9M cash at September 30, 2026, expected to fund operations into the second half of 2029
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Patrick Vink resigned November 10 after 11 years, without reported disputes, creating a Class II board vacancy
- William Ho appointed to fill the Class II seat, adding clinical development and immunotherapy expertise
Item 5.02: Departure/Appointment of Directors or Principal Officers
- COO Timothy Keutzer retiring December 31, 2026 after 11 years with Spero Therapeutics
- Transition consulting expected through approximately February 28, 2027, terminable on 15 days’ notice
AI summaries of SPRO 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SPRO
Don't miss the next SPRO filing
- Alerts as it files. A push when SPRO files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SPRO, by share count.
- Ask anything. An AI agent that reads every SPRO filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| HO WILLIAM | A | Nov 10, 2026 | 100,000 | - |
| Rajavelu Esther | Sell | Nov 9, 2026 | 40,851 | $1.04 |
| Zack Debra | A | Aug 3, 2026 | 162,311 | - |
| Zack Debra | A | Aug 3, 2026 | 324,675 | - |
| Pottage John C Jr | A | Jun 23, 2026 | 10,000 | - |
| Pottage John C Jr | A | Jun 23, 2026 | 20,000 | - |
| THOMAS FRANK E | A | Jun 23, 2026 | 10,000 | - |
| Deshpande Milind | A | Jun 23, 2026 | 20,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $933K | $371K | $12.6M |
| Operating Income | $21.5M | -$73.4M | $6.3M |
| Net Income | $22.8M | -$68.6M | $8.6M |
| Op. Margin | 2302.4% | -19773.9% | 50.2% |
| Net Margin | 2444.4% | -18481.4% | 68.1% |
| Balance Sheet | |||
| Total Assets | $182.4M | $110.5M | $68.9M |
| Equity | $106.9M | $46.1M | $59.0M |
| ROE | 21.3% | -148.7% | 14.5% |
| Per Share | |||
| EPS | - | $-1.27 | $0.15 |
| Cash Flow | |||
| Operating CF | -$33.0M | -$23.4M | -$12.6M |
Source: XBRL data in Spero Therapeutics Inc (SPRO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate SPRO share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 17 | $11.3M |
| Q2 2026 | 20 | $19.3M |
| Q1 2026 | 16 | $19.6M |
| Q4 2025 | 18 | $19.4M |
| Q3 2025 | 17 | $14.4M |
| Q2 2025 | 15 | $20.3M |
| Q1 2025 | 14 | $4.6M |
| Q4 2024 | 12 | $6.8M |
- Renaissance Technologies LLC+461.9K (+49%)
- Morgan Stanley+257.7K (+28198%)
- Raymond James Financial+233.9K (+45%)
- Prudential Financial+194.3K (+1868%)
- Invesco Ltd+101.3K (+158%)
- Dimensional Fund Advisors−183.5K (-67%)
- Two Sigma Investments−115.6K (-30%)
- BlackRock−146 (-0%)
- Citadel Advisors LLC+726.0K
- StoneX Group Inc.+38.2K
- Alphabet Inc−890.0K
- Goldman Sachs Group−257.0K
- Millennium Management−19.3K
- Citigroup−9.6K
- FMR LLC (Fidelity)−300
Source: 13F-HR filings on SEC EDGAR (aggregated from 129 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SPRO filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 12, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 8-K | Nov 10, 2026 | - | Analysis | - |
| 4 | Nov 10, 2026 | - | - | - |
| 4 | Nov 10, 2026 | - | - | - |
| 8-K | Oct 27, 2026 | - | Analysis | - |
| 8-K | Aug 28, 2026 | - | Analysis | - |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| 10-Q | Aug 12, 2026 | Jun 30, 2026 | - | |
| 4 | Aug 6, 2026 | - | - | - |
| 8-K | Jul 14, 2026 | - | Analysis | - |
| 4 | Jun 25, 2026 | - | - | - |
| 4 | Jun 25, 2026 | - | - | - |
| 4 | Jun 25, 2026 | - | - | - |
| 4 | Jun 25, 2026 | - | - | - |
| 8-K | Jun 25, 2026 | - | - | - |
| 4 | Jun 25, 2026 | - | - | - |
| 4 | Jun 25, 2026 | - | - | - |
| 4 | Jun 25, 2026 | - | - | - |
| 8-K | Jun 22, 2026 | - | - | - |
| 10-Q | May 13, 2026 | Mar 31, 2026 | - | |
| 8-K | May 13, 2026 | - | - | |
| 4 | May 6, 2026 | - | - | |
| 8-K | Mar 26, 2026 | - | - | - |
| 10-K | Mar 26, 2026 | Dec 31, 2025 | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
SPRO SEC filings: frequently asked questions
Are SPRO insiders buying or selling?
In the last 90 days, Spero Therapeutics Inc (SPRO) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $42,485 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold SPRO stock?
As of September 30, 2026, the largest Spero Therapeutics Inc (SPRO) holders among the 13F filers tracked by SignalX were Pfizer Inc ($2.9 million), Vanguard Capital Management LLC ($2.5 million), Renaissance Technologies LLC ($1.7 million), Raymond James Financial ($914,000), Citadel Advisors LLC ($878,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was SPRO's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Spero Therapeutics Inc (SPRO) reported revenue of $12.6 million (up 3292.5% from FY2024) and net income of $8.6 million. Diluted EPS was $0.15. The figures come from the XBRL data in the 10-K.
What did SPRO report in its latest 8-K?
Spero Therapeutics Inc (SPRO) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Third-quarter results for period ended September 30, 2026 announced by Spero Therapeutics.
What are the latest SPRO SEC filings?
Spero Therapeutics Inc (SPRO) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 10, 2026.
What is SPRO's SEC CIK number?
Spero Therapeutics Inc (SPRO)'s SEC Central Index Key (CIK) is 1701108. EDGAR lists every SPRO filing under that number.
Ask anything about SPRO
The research agent reads SPRO's filings, financials, insider trades and 13F holders, then answers with sources.